ACHV Achieve Life Sciences Inc.
- Stocks
- Healthcare
- NASDAQ: ACHV
Price (delayed)
$4.75
Market cap
$242.75M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.46
Enterprise value
$200.83M
Relative Growth:
Rel. Growth:
2
Relative Strength:
Rel. Strength:
90
Relative Valuation:
Rel. Valuation:
N/A
Relative Profitability:
Rel. Profitability:
0
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company
Highlights
The quick ratio has soared by 98% QoQ and by 45% YoY
The debt has contracted by 44% YoY
ACHV's net income has shrunk by 83% YoY and by 9% QoQ
Achieve Life Sciences's EPS has decreased by 34% YoY and by 9% QoQ
Key stats
What are the main financial stats of ACHV
Market
Valuations
Earnings
Shares outstanding
51.1M
Market cap
$242.75M
Enterprise value
$200.83M
Price to earnings (P/E)
N/A
Price to book (P/B)
3.95
Price to sales (P/S)
N/A
PEG
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$50.11M
Net income
-$50.42M
EBIT
-$49.48M
EBITDA
-$49.25M
Free cash flow
-$39.72M
Per share
Balance sheet
Liquidity
EPS
-$1.46
EPS diluted
-$1.46
Free cash flow per share
-$1.15
Book value per share
$1.2
Revenue per share
$0
TBVPS
$1.64
Total assets
$58.94M
Total liabilities
$17.27M
Debt
$9.96M
Equity
$41.67M
Working capital
$48.33M
Debt to equity
0.24
Current ratio
6.64
Quick ratio
6.46
Net debt/EBITDA
0.85
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-116.7%
Return on equity
-193.5%
Return on invested capital
-224%
Return on capital employed
-98.2%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ACHV stock price
How has the Achieve Life Sciences stock price performed over time
Intraday
-3.65%
1 week
-9.35%
1 month
50.32%
1 year
-7.23%
YTD
34.94%
QTD
50.79%
Financial performance
How have Achieve Life Sciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$50.11M
Net income
-$50.42M
Gross margin
N/A
Net margin
N/A
Achieve Life Sciences's operating income has shrunk by 98% YoY and by 9% QoQ
ACHV's net income has shrunk by 83% YoY and by 9% QoQ
Price vs fundamentals
How does ACHV's price correlate with its fundamentals
Growth
What is Achieve Life Sciences's growth rate over time
Valuation
What is Achieve Life Sciences stock price valuation
P/E
N/A
P/B
3.95
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Achieve Life Sciences's EPS has decreased by 34% YoY and by 9% QoQ
The P/B is 81% less than the 5-year quarterly average of 21.4 and 25% less than the last 4 quarters average of 5.5
Efficiency
How efficient is Achieve Life Sciences business performance
ACHV's ROA has dropped by 89% year-on-year and by 13% since the previous quarter
Achieve Life Sciences's return on invested capital has shrunk by 68% QoQ and by 42% YoY
Achieve Life Sciences's return on equity has shrunk by 66% YoY and by 10% QoQ
Dividends
What is ACHV's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ACHV.
Financial health
How did Achieve Life Sciences financials performed over time
The total assets has soared by 115% from the previous quarter but it has contracted by 9% YoY
The quick ratio has soared by 98% QoQ and by 45% YoY
The debt is 76% less than the equity
Achieve Life Sciences's debt to equity has plunged by 75% from the previous quarter and by 43% YoY
The debt has contracted by 44% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.